Vascular effects of long-term propranolol administration after chronic nitric oxide blockade

European Journal of Pharmacology

Volumn 571, Issue 2-3, 2007, Pages 189-196

  Priviero, Fernanda B M ^a   Teixeira, Cleber E ^a   Claudino, Mário A ^a   Nucci, Gilberto De ^a   Zanesco, Angelina ^b   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

adrenoceptor antagonist; Arterial reactivity; Endothelial dysfunction; Endothelium derived hyperpolarizing factor; Nitric oxide bioavailability

Indexed keywords

ACETYLCHOLINE; CALCIUM CHLORIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; POTASSIUM CHLORIDE; PROPRANOLOL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BIOLOGICAL FACTORS; BLOOD PRESSURE; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYPERTENSION; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGLYCERIN; POTASSIUM; PROPRANOLOL; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 34548474532     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.060     Document Type: Article

References (44)

1. Adachi T., Shinomura T., Nakao S., Kurata J., Murakawa M., Shichino T., Seo N., and Mori K. Chronic treatment with nitric oxide synthase (NOS) inhibitor profoundly reduces cerebellar NOS activity and cyclic guanosine monophosphate but does not modify minimum alveolar anesthetic concentration. Anesth. Analg. 81 (1995) 862-865
2. Arumanayagam M., Chan S., Tong S., and Sanderson J.E. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J. Cardiovasc. Pharmacol. 37 (2001) 48-54
3. Aruoma O.I., Smith C., Cecchini R., Evans P.J., and Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. A physiologically-significant process?. Biochem. Pharmacol. 42 (1991) 735-743
4. Baylis C., Mitruka B., and Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90 (1992) 278-281
5. 2-adrenergic receptor-mediated nitric oxide production. Circulation 102 (2000) 677-684
6. Edwards G., and Weston A.H. Potassium and potassium clouds in endothelium-dependent hyperpolarizations. Pharmacol. Res. 49 (2004) 535-541
7. Elmarakby A.A., Williams J.M., and Pollock D.M. Targeting sources of superoxide and increasing nitric oxide bioavailability in hypertension. Curr. Opin. Investig. Drugs 4 (2003) 282-290
8. Erley C.M., Rebmann S., Strobel U., Schmidt T., Wehrmann M., Osswald H., and Risler T. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp. Nephrol. 3 (1995) 293-299
9. Feletou M., and Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1215-1225
10. Gao Y.S., Nagao T., Bond R.A., Janssens W.J., and Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol. 17 (1991) 964-969
11. Garcia-Estan J., Ortiz M.C., O'Valle F., Alcaraz A., Navarro E.G., Vargas F., Evangelista S., and Atucha N.M. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Clin. Sci. 110 (2006) 227-233
12. + channel blockers involved in EDHF-mediated responses in rat superior mesenteric artery. Br. J. Pharmacol. 134 (2001) 1021-1028
13. Hill C.E., Hickey H., and Sandow S.L. Role of gap junctions in acetylcholine-induced vasodilation of proximal and distal arteries of the rat mesentery. J. Auton. Nerv. Syst. 81 (2000) 122-127
14. Hobbs A.J., Higgs A., and Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 191-220
15. Janero D.R., Lopez R., Pittman J., and Burghardt B. Propranolol as xanthine oxidase inhibitor: implications for antioxidant activity. Life Sci. 44 (1989) 1579-1588
16. Kataoka C., Egashira K., Inoue S., Takemoto M., Ni W., Koyanagi M., Kitamoto S., Usui M., Kaibuchi K., Shimokawa H., and Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39 (2002) 245-250
17. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction. 2nd Edn. (1993), Raven Press, New York
18. Khattab M.M., Mostafa A., and Al-Shabanah O. Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. Kidney Blood Press Res. 28 (2005) 243-250
19. Kitamoto S., Egashira K., Kataoka C., Usui M., Koyanagi M., Takemoto M., and Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J. Hypertens. 18 (2000) 1795-1800
20. 2+ release and entry during contraction elicited by norepinephrine in rat resistance arteries. Am. J. Physiol. 276 (1999) H300-H308
21. Lagaud G.J., Skarsgard I.L., and Breemen C.V. Heterogeneity of endothelium-dependent vasodilation in pressurized cerebral and small mesenteric resistance arteries of the rat. J. Pharmacol. Exp. Ther. 290 (1999) 832-839
22. Maia E.R., Villacorta H., Subietta C.G., Munhoz C., Romeo Filho L.J., and Mesquita E.T. Use of propranolol in heart failure patients: safety, tolerability, and effects on left ventricular function. Rev. Port. Cardiol. 20 (2001) 383-399
23. Mak I.T., and Weglicki W.B. Protective effect of β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ. Res. 63 (1988) 262-266
24. Mak I.T., and Weglicki W.B. Potent antioxidant properties of 4-hydroxyl-propranolol. J. Pharmacol. Exp. Ther. 308 (2004) 85-90
25. Marano G., Palazzesi S., Fadda A., Vergari A., and Ferrari A.U. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J. Hypertens. 20 (2002) 763-769
26. Moreno Jr. H., Metze K., Bento A.C., Antunes E., Zatz R., and De Nucci G. Chronic nitric oxide inhibition as a model of ischemic cardiopathy. Basic Res. Cardiol. 91 (1996) 248-255
27. Mostaghim R., Maddox Y.T., and Ramwell P.W. Endothelial potentiation of relaxation response to beta adrenoceptor blocking agents. J. Pharmacol. Exp. Ther. 239 (1986) 797-801
28. Okazaki H., Minamino T., Tsukamoto O., Kim J., Okada K., Myoishi M., Wakeno M., Takashima S., Mochizuki N., and Kitakaze M. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. Hypertens. Res. 29 (2006) 277-284
29. 2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic inhibition of nitric oxide synthesis in the rat. Eur. J. Pharmacol. 373 (1999) 195-200
30. Pacca S.R., De Azevedo A.P., De Oliveira C.F., De Luca I.M.S., De Nucci G., and Antunes E. Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 39 (2002) 201-207
31. Priviero F.B., Teixeira C.E., Toque H.A., Claudino M.A., Webb R.C., De Nucci G., Zanesco A., and Antunes E. Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade. Clin. Exp. Pharmacol. Physiol. 33 (2006) 448-455
32. Reiter M.J. Cardiovascular drug class specificity: beta-blockers. Progr. Cardiovasc. Dis. 47 (2004) 11-33
33. Ribeiro M.O., Antunes E., De Nucci G., Lovisolo S.M., and Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20 (1992) 298-303
34. Richards D.A., Woodings E.P., and Maconochie J.G. Comparison of the effects of labetolol and propranolol in healthy men at rest and during exercise. Br. J. Clin. Pharmacol. 4 (1977) 15-21
35. Rokutanda M., Araki S., and Sakanashi M. A pharmacological investigation on a possible calcium antagonistic action of propranolol. Arch. Int. Pharmacodyn. Ther. 262 (1983) 99-108
36. Rummery N.M., and Hill C.E. Vascular gap junctions and implications for hypertension. Clin. Exp. Pharmacol. Physiol. 31 (2004) 659-667
37. Teixeira C.E., and Webb R.C. Targeting the vascular RhoA-Rho-kinase signaling pathway in hypertension. Drug Discov. Today: Ther. Strategies 2 (2005) 193-199
38. Usui M., Egashira K., Tomita H., Koyanagi M., Katoh M., Shimokawa H., Takeya M., Yoshimura T., Matsushima K., and Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the athogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 101 (2000) 305-310
39. van den Meiracker A.H., Man In't Veld A.J., Boomsma F., Fischberg D.J., Molinoff P.B., and Schalekamp M.A. Hemodynamic and β-adrenergic receptor adaptations during long-term β-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 80 (1989) 903-914
40. Webb R.C. Smooth muscle contraction and relaxation. Adv. Physiol. Educ. 27 (2003) 201-206
41. Weglicki W.B., Mak I.T., and Simic M.G. Mechanisms of cardiovascular drugs as antioxidants. J. Mol. Cell Cardiol. 22 (1990) 1199-1208
42. Wu X., Somlyo A.V., and Somlyo A.P. Cyclic GMP-dependent stimulation reverses G-protein-coupled inhibition of smooth muscle myosin light chain phosphate. Biochem. Biophys. Res. Commun. 220 (1996) 658-663
43. Zanesco A., Spadari-Bratfisch R.C., and Barker L.A. Sino-aortic denervation causes right atrial beta adrenoceptor down-regulation. J. Pharmacol. Exp. Ther. 280 (1997) 677-685
44. Zatz R., and Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 32 (1998) 958-964